Pfizer, Alliance For Lupus Research To Co-Fund Translational Projects
This article was originally published in The Pink Sheet Daily
Pfizer’s partnership with the Alliance for Lupus Research to co-fund translational projects within the context of the pharma’s CTI program is a first. It’s a novel way to speed promising science into the clinic. But can Pfizer, a non-profit research foundation, and academic researchers reconcile their new roles and variant cultures to make the model work?
You may also be interested in...
That helping patients ultimately will lead to return for investors was the underlying theme of this year’s Partnering For Cures conference in New York Nov. 3-5. Panels looked at issues pertaining to mental health, biotech funding, finding a cure for lupus and clinical trial protocols for cardiovascular disease.
Kyowa Hakko Kirin is committed to expansion, and the deal with Ultragenyx for a first-in-class therapy of a rare bone disorder is small but establishes a clinical trial foothold overseas
Pfizer’s Centers for Therapeutic Innovation program has grown in less than three years to include 24 academic partners. First drug candidate to emerge from the research model is expected to enter the clinic this year, and Pfizer’s investment in CTI has grown.